EDMONTON, Alberta, Nov. 8 /PRNewswire-FirstCall/ -- Medical Services International Inc. sales continue to meet expectations. Medical Services International is pleased to announce that based on orders received to date from distributors that the projections of 400,000 VScan test kits for the second quarter will be exceeded. Based on information supplied by distributors, the Company now anticipates orders in excess of 500,000 VScan test kits in the second quarter.
The addition of a follow up TB test combined with the existing VScan TB test kit has created significant interest in the market. The Company is moving as quickly as possible to make the follow up test available for regulatory testing in our major markets.
About VScan
The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria, and Prostate Cancer. The kits cannot be sold in Canada.
Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or media contact Bill Whitehead at (416) 822 5883 or http://www.medicalservicesintl.com or http://www.minerva-biotech.com .
NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
Medical Services International Inc.CONTACT: Robert Talbot, +1-780-430-6363, or media, Bill Whitehead,+1-416-822-5883, both for Medical Services International Inc.